|
Citius Pharmaceuticals ، Inc. (CTXR) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Citius Pharmaceuticals, Inc. (CTXR) Bundle
Discover Citius Pharmaceuticals ، Inc. (CTXR) القيمة الحقيقية مع حاسبة DCF المتقدمة لدينا! اضبط الافتراضات الأساسية ، واستكشاف السيناريوهات المختلفة ، وقم بتقييم كيفية تأثير العوامل المختلفة على تقييم Citius Pharmaceuticals ، Inc. (CTXR) - كل ذلك ضمن قالب Excel الشامل.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -17.4 | -22.9 | -32.9 | -36.7 | .0 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .2 | .2 | .2 | .2 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -17.5 | -23.0 | -33.1 | -36.9 | .0 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 13.9 | 70.1 | 41.7 | 26.5 | 3.3 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | 8.3 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.9 | 1.3 | 1.2 | 2.9 | 4.9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | -40.0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | -1.48 | -1.48 | -1.48 | -1.48 | -1.48 | -1.48 | -1.48 | -1.48 | -1.48 | -1.48 |
| EBITAT | -17.7 | -23.1 | -33.6 | -37.6 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -15.7 | -63.5 | -33.6 | -35.6 | -6.3 | 3.3 | .0 | .0 | .0 | .0 |
| WACC, % | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 | 10.1 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 3.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 3 | |||||||||
| Net Debt | -3 | |||||||||
| Equity Value | 6 | |||||||||
| Diluted Shares Outstanding, MM | 174 | |||||||||
| Equity Value Per Share | 0.03 |
What You Will Get
- Pre-Filled Financial Model: Citius Pharmaceuticals' actual data facilitates accurate DCF valuation.
- Full Forecast Control: Modify revenue growth, margins, WACC, and other essential drivers.
- Instant Calculations: Automatic updates provide immediate results as you adjust inputs.
- Investor-Ready Template: A polished Excel file crafted for professional-level valuation.
- Customizable and Reusable: Designed for adaptability, allowing repeated application for comprehensive forecasts.
Key Features
- 🔍 Real-Life CTXR Financials: Pre-filled historical and projected data for Citius Pharmaceuticals, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Citius Pharmaceuticals’ intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Citius Pharmaceuticals’ valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Obtain the comprehensive Excel file containing Citius Pharmaceuticals, Inc.'s (CTXR) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and instantly compare the results.
- Make Decisions: Leverage the valuation outcomes to inform your investment choices.
Why Choose This Calculator for Citius Pharmaceuticals, Inc. (CTXR)?
- Accurate Data: Utilize real Citius Pharmaceuticals financials for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you from starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: Simple design and clear instructions ensure accessibility for all users.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive and accurate valuation models for Citius Pharmaceuticals, Inc. (CTXR) portfolio assessments.
- Pharmaceutical Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the company.
- Consultants and Advisors: Deliver precise valuation insights to clients interested in Citius Pharmaceuticals, Inc. (CTXR).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech firms like Citius Pharmaceuticals, Inc. (CTXR) are valued in the market.
What the Template Contains
- Historical Data: Includes Citius Pharmaceuticals' past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Citius Pharmaceuticals' intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Citius Pharmaceuticals' financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.